Oncology Institute (DFPH) Preferred Stock Liabilities (2020 - 2021)
Oncology Institute's (DFPH) quarterly Preferred Stock Liabilities came in at $230.0 million in Q3 2021, up 767.68% YoY from $26.5 million in Q3 2020, and up 14.7% on a QoQ basis from $200.5 million in Q2 2021.
Oncology Institute (DFPH) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Oncology Institute (DFPH) has 2 years of Preferred Stock Liabilities data on file, last reported at $230.0 million in Q3 2021.
- Quarterly Preferred Stock Liabilities rose 767.68% year-over-year to $230.0 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $230.0 million (up 767.68% YoY) and the FY2020 annual result came in at $230.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities rose to $230.0 million in Q3 2021, from $200.5 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $230.0 million in Q1 2020 to a low of $26.5 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | HCA Healthcare | 88.19 Bn | 90.61 Bn | 15.19 Bn | - |
| 2 | Tenet Healthcare | 21.59 Bn | 21.56 Bn | 4.45 Bn | - |
| 3 | Encompass Health | 12.19 Bn | 12.86 Bn | 1.34 Bn | - |
| 4 | Davita | 11.52 Bn | 12.39 Bn | 1.16 Bn | - |
| 5 | Ensign | 10.59 Bn | 10.27 Bn | 306.24 Mn | - |
| 6 | Universal Health Services | 8.79 Bn | 8.72 Bn | 3.29 Bn | - |
| 7 | Pacs | 7.04 Bn | 6.88 Bn | 338.46 Mn | - |
| 8 | Chemed | 6.96 Bn | 6.92 Bn | 221.47 Mn | - |
| 9 | Concentra Group Holdings Parent | 4.52 Bn | 4.38 Bn | 192.10 Mn | - |
| 10 | Oncology Institute | 201.94 Mn | 160.85 Mn | 27.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 230.00 Mn |
| Jun 30, 2021 | 200.53 Mn |
| Mar 31, 2021 | 206.65 Mn |
| Dec 31, 2020 | 230.00 Mn |
| Sep 30, 2020 | 26.51 Mn |
| Jun 30, 2020 | 205.91 Mn |
| Mar 13, 2020 | 230.00 Mn |